US transformation has been successful, says Novo Nordisk's country head
Pharmaceutical firm Novo Nordisk is very close to attaining the goals set for its US operation. According to Doug Langa, Novo’s head in the country, diabetes drug Ozempic is sprinting ahead whereas pill treatment Rybelsus is lagging behind.
by Benjamin Werner Christensen, translated by daniel pedersen
Pharmaceutical firm Novo Nordisk has made it in the US, at least according to the company’s head of operations in the country, Doug Langa.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
